Share
1
item
избран
Получете достъп до изключителни дерматологични услуги, за да подобрите своите професионални знания: над 500 визуални материала за патологии, клинични случаи и експертни видеа
Възползвайте се от ценни функции: аудио слушане, материали за споделяне с вашите пациенти
Бъдете информирани за предстоящи събития и уебинари, последни научни публикации и продуктови иновации
Вече имате профил? Влезте тук
Reports written by Dr. Oriol Yélamos (Dermatologist, Spain)
By
Dr. Oriol Yelamos
Speaker: Prof. Caroline Robert (Paris, France)
Reports written by Dr. Oriol Yélamos
We have different types of biomarkers: prognostic biomarkers, predictive biomarkers (they predict treatment response), and both prognostic and predictive biomarkers.
What you want on a biomarker is very high sensitivity and specificity with an area under the curve close to 1.
Staging (CT scans, LDH values, B-RAF status, comorbidities...) is per se a way to stratify our patients.
We are going to take a look at different biomarkers.
Patients with high LDH still benefit from new therapies (immunotherapy, targeted therapies), but they have a worse outcome compared with patients with normal LDH. Why is that? We believe that high LDH means high tumor burden, but also it is related with the tumor microenvironment, metabolism and a more acid environment, which negatively impacts on oncogenic pathways.
There are 5 different isoforms of LDH, which have critical roles in metabolism. What happens is that when we ask for LDH determination on a routine blood test we are not really measuring LDH, but a reaction led by the LDH enzyme. So, Dr. Robert's group studied the different isoforms of LDH and showed that LDH1 is good, LDH4 is bad. They have shown then that it is good to look not only if LDH is high or normal, but to assess the LDH1/LDH4 ratio.
PD-L1 is expressed in tumor cells, and induced by IFN-γ (interferon-gamma). The problem is that PD-L1 is not homogenously expressed in the tumor, and also can be expressed by cells around the tumor. Intuitively, treatment response would be better if PD-L1 expression was high; there is, however, no clear statistical association, although there's a trend.
There's a new test: PD-1/PD-L1 proximity ligation assay, which seems a promising test to predict treatment response. However, it's still not widely available and very expensive.
The rationale is the following: more mutations, more neoantigens and therefore better treatment response. The problem is that although there's a trend towards more response in high-TMB tumors, not all studies show this. Hence, the importance is not the number of mutations, but how many clonal mutations are found.
The combination of multiple molecular techniques is the future but can't be used routinely now because of high cost.
Multiple studies analyze circulating tumor DNA (ctDNA). ctDNA is rarely found on the blood tests of early melanomas but is commonly found (90%) is advanced melanoma, and this is why it can be potentially used to detect aggressive melanomas. The problems are related to the detection technique, since nowadays we don’t know the threshold of ctDNA that is clinically relevant. Hence, liquid biopsy nowadays is only done for research purposes since there are no standard methods. However, this is definitely one of the most promising techniques.
Some endothelial cells may be good treatment biomarkers for ICI.
Anti-PD-1 (anti programmed-cell death 1 antibodies) response is also associated with some gut germs. There will be a whole session on this topic.
Patients who respond early to ICI they do very well. So, this can be a very good marker.
Позволявайки тези услуги на трети лица, Вие приемате техните бисквитки и употребата на технологии за проследяване, необходими за правилното им функциониране.